Dermatology Annual Skin-Cancer Screening Recall: 5.5% Response on 600 Patients

The challenge

Coastal Dermatology Associates ran a high-volume practice in a sun-belt market where annual skin-cancer screening should have been a steady recurring revenue line. Their EMR showed 2,400 patients with active charts, but only 1,800 had been seen in the past 14 months. The 600-patient gap was annual full-body screenings that had drifted past their schedule, and in a Florida market that is a clinical concern as much as a revenue gap.

Existing recall was the EMR’s automated email plus an SMS reminder 30 days past due. Open rates on email ran 19%, click 1.6%, and bookings tracked to the recall blast were under 20 per quarter from a 600-patient pool. The senior partner had pushed for phone-call recall, but the front-desk team was already at 90% utilization on inbound calls and same-day rescheduling, so adding 600 outbound dials wasn’t realistic.

The owner-derms wanted three things: a way to break the email-fatigue cycle for older Florida patients (median age 62 in this segment), a recall that reached first the patients the providers worried most about losing track of, and something they could run every quarter without a labor surge.

The PostKnock approach

Playbook used: Annual Skin Cancer Screening. The playbook has three waves; this practice ran the first two, postcard only.

Pulling the list

The list came from an EMR report: active patients whose last visit was more than a year ago, minus anyone with an appointment already booked, anyone deceased or transferred, and anyone who had asked not to be contacted. Sarasota has a large part-year population, so the front desk also checked which address each patient actually receives mail at that time of year. The export was an Excel file. For any EMR the route is the same: export a CSV or Excel file, then import it.

What went into the file was contact data and a recall date: name, mailing address, phone, last-visit date. Diagnoses, procedure and billing codes, biopsy history and visit notes stayed in the EMR. That follows PostKnock’s own guidance to upload contact data, not health data. Whether a given use fits your policies is a question for your compliance officer.

The providers sorted the 600 into three tiers using their own clinical judgment: high risk (180), standard risk (280) and lower risk (140). The reasons never left the chart. The import file carried one letter per patient in a Priority column, which PostKnock reads (A, B and C map to a priority score, with a preview before the import commits) so higher-priority patients go out first when a daily send limit applies.

The first card

Wave 1 went as a 6x9 postcard using the playbook’s “Time For Your Annual Skin Check” copy, written in a clinical tone: no “glow up” cosmetic framing, no offers, no discounts. Skin-cancer screening is a category where a discount undermines trust. The card said it had been more than a year since the patient’s last visit, carried a QR code to the practice’s online booking calendar (filtered to screening-only slots) and a phone number. The high-priority tier got a more direct ask, “Please call us this week,” with no reason given. The senior partner approved both versions.

What stayed off the card

• The patient’s name on the message side. It appears only in the USPS address block.
• Any diagnosis, biopsy or procedure history, and any “follow-up on your mole” language.
• Risk labels. The tier letter exists in the import file and nowhere on the card.
• Photos of skin conditions.
• A coverage promise. The playbook’s default copy mentions insurance, and this practice left it out. Plans differ on how they cover a full-body exam when you have no complaint, and the U.S. Preventive Services Task Force’s 2023 statement rated routine visual skin exams for symptom-free adults “I”, meaning the evidence is insufficient to recommend for or against (USPSTF). If you keep a coverage line, check it against what your payers actually do.

Timing and wave 2

Wave 1 landed in the last week of April, ahead of May, when the American Academy of Dermatology runs a month-long skin cancer awareness campaign that opens with Melanoma Monday. A card that arrives while the topic is already in the news has a little help, though it is no substitute for a clear ask. Wave 2 dropped at week 4 only to the patients who hadn’t booked, using the playbook’s “Early Detection Saves Lives” angle in a shorter layout: early skin changes can be easy to miss on your own. Evidence-led, not alarmist, and no numbers printed on the card. Total: ~960 pieces (Wave 1 full 600 + Wave 2 ~360 to everyone still in the sequence), 6-week campaign. The campaign was designed to be re-runnable on a rolling cohort each quarter.

Why no phone calls

The owner’s labor constraint was real, so this practice did not use the Call Queue. With Pro, the playbook adds a call 5 business days after delivery of wave 1 (adjustable from 1 to 10) and another after wave 2, using a calm, clinical script that opens by referring to the card and offers to find a time. If the front desk later wants calls, the pace settings tie mail volume to the hours it can dial, so the queue never outgrows the people working it.

Campaign timeline

Week 0

EMR export, 3-tier risk segmentation, copy review with senior partner.

Week 1

Wave 1 drops (600 cards). High-risk segment gets stronger CTA.

Week 2-3

Bookings flow. 19 screenings scheduled.

Week 4

Wave 2 drops (~360 cards) to non-responders. Evidence-led creative.

Week 5-6

Tail bookings. 14 incremental screenings.

Week 7

Final tally: 33 booked. Two suspicious lesions detected; one referred to MOHS.

Results

Thirty-three booked screenings on 600 unique patients lands at 5.5%, within the 3-6% healthcare recall range, on the higher end because the campaign avoided promotional framing in a category where seriousness reads as trustworthy. Visible revenue is modest by dermatology standards: 33 screenings at $300 average ($9,900, mostly insurance-paid). But the screening tail is what matters: two lesions flagged biopsy, one referred to MOHS surgery (averaging $2,200-$3,800 per case), and four high-mole-burden patients booked into ongoing 6-month surveillance.

Campaign cost ran $3,786: $902 in postcards (960 at $0.94), $297 in Pro plan, and $2,587 in list-prep + EMR-export labor. The headline 2.6x ROI on visible revenue understates the campaign: the MOHS referral alone bridges the gap, and the four surveillance patients now generate $1,200/year in recurring screenings each. Year-2 ROI on this same cohort lands closer to 5.5x without sending another card.

What we’d do differently

• Leaving the discount off fit the category. Skin-cancer screening is trust-driven, and promotional framing tends to cost credibility. We'd default to no discount on dermatology screening recalls.
• Risk-tier segmentation paid off. The high-risk segment booked at 9.4% (17 of 180), the standard at 4.6% (13 of 280), the low-risk at 2.1% (3 of 140). Future campaigns should weight mailing volume toward risk-tier 1-2 and de-prioritize tier 3.
• We should have included a short note about the practice's MOHS capability. The one MOHS referral bumped revenue meaningfully; surfacing the in-house capability could have generated 1-2 additional conversions.
• Keep the clinical split in the chart. The tiers worked, but only a letter went into the import file and nothing on the card hinted at it. Make the card say only what billing and the providers will stand behind.
• Report two numbers. The screening revenue is the first-year return. The surveillance patients are lifetime upside: see customer lifetime value for how to value them without inflating the headline ROI, and how to count a response honestly for matching bookings to the mailed list.